How much cash does Bicara Therapeutics generate?

Bicara Therapeutics (BCAX) generated -$116.2M in operating cash flow over the trailing twelve months.

What is Bicara Therapeutics's free cash flow?

After $340.0K of capital expenditures, Bicara Therapeutics's free cash flow was -$116.6M over the trailing twelve months, down 32.0% year over year.

Where does Bicara Therapeutics's cash flow data come from?

Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Bicara Therapeutics BCAX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$157.32M-14.0%	-$137.95M-13.5%	-$121.52M-18.4%	-$102.67M-11.2%	-$92.33M-35.8%
Depreciation and amortization	$130K+23.8%	$105K+36.4%	$77K+13.2%	$68K+9.7%	$62K+10.7%
Stock-based compensation	$17.41M+16.0%	$15.01M+9.2%	$13.74M+13.0%	$12.16M+25.3%	$9.7M+31.1%
Change in other assets	-$3.56M+36.3%	-$5.58M-147%	$11.83M-0.9%	$11.94M-5.0%	$12.56M-25.7%
Non-cash operating lease expense	——	——	——	——	——
Change in operating lease liabilities	-$1.06M-13.2%	-$932K-168%	-$348K-238%	-$103K-5,250%	$2K-97.5%
Net cash from operating activities	-$116.24M-8.8%	-$106.83M+5.4%	-$112.98M-11.9%	-$100.96M-14.4%	-$88.27M-18.1%
Capital expenditures	$340K+21.4%	$280K+241%	$82K+70.8%	$48K-28.4%	$67K-5.6%
Proceeds from maturities/sales of investments	——	——	——	——	——
Net cash from investing activities	-$217.51M+31.7%	-$318.45M-34.8%	-$236.16M—	——	——
Proceeds from issuance of common stock	$191.26M+548%	$29.5M—	$0-100%	$332.61M-0.2%	$333.34M0.0%
Net cash from financing activities	$195.15M+505%	$32.26M+3,029%	$1.03M-99.7%	$334.73M-0.2%	$335.33M+0.1%
Net increase (decrease) in cash	-$138.6M+64.7%	-$393.03M-55.2%	-$253.22M-177%	$328.62M-3.9%	$341.88M-3.7%
Income taxes paid	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Depreciation	$130K+23.8%	$105K+36.4%	$77K+13.2%	$68K+9.7%	$62K+10.7%
Operating lease liabilities	-$1.06M-13.2%	-$932K-168%	-$348K-238%	-$103K-5,250%	$2K-97.5%
Increase (Decrease) in Prepaid Expense and Other Assets	-$3.56M+36.3%	-$5.58M-147%	$11.83M-0.9%	$11.94M-5.0%	$12.56M-25.7%
Operating lease right-of-use asset amortization	——	——	——	——	——
Non-cash lease expense	——	$895K+37.3%	$652K+59.4%	$409K+146%	$166K+316%
Proceeds from disposition of marketable securities and other investments	——	——	——	——	——
Offering costs included in accounts payable and accrued expenses	——	——	——	——	——
Free cash flow	-$116.58M-8.8%	-$107.11M+5.3%	-$113.06M-11.9%	-$101M-14.3%	-$88.34M-18.1%
Free cash flow	-$116.58M-8.8%	-$107.11M+5.3%	-$113.06M-11.9%	-$101M-14.3%	-$88.34M-18.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Bicara Therapeutics generate?: Bicara Therapeutics (BCAX) generated -$116.2M in operating cash flow over the trailing twelve months.
What is Bicara Therapeutics's free cash flow?: After $340.0K of capital expenditures, Bicara Therapeutics's free cash flow was -$116.6M over the trailing twelve months, down 32.0% year over year.
Where does Bicara Therapeutics's cash flow data come from?: Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.